Rapamycin vs Sermorelin
FDA Approved vs Well Studied
monitor Mechanism-based · 47% Both Rapamycin and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Rapamycin Sermorelin
Weight 914.17 Da 3,358 Da
Half-life ~62 hours 10-12 minutes
Chain — 29 amino acids
Type Macrolide lactone (C51H79NO13) GHRH analog
Key Benefits
Rapamycin
01 Lifespan extension demonstrated in every model organism tested (yeast, worms, flies, mice)
02 Upregulation of autophagy and cellular quality control mechanisms
03 Reduction of senescent cell burden and associated inflammatory secretome
04 Improved immune function at low pulsed doses (paradoxical immune enhancement)
05 Reduced age-related inflammation (inflammaging) via mTORC1 inhibition
06 Enhanced mitochondrial function and biogenesis
07 Potential reduction in age-related cancer risk through growth pathway suppression
08 Improved vaccine response in elderly populations at low intermittent doses
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Rapamycin
3-6 mg once weekly (longevity protocol) / Once weekly (pulsed longevity) or daily (immunosuppressive)
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Rapamycin
Mouth sores / aphthous ulcers (most common, usually dose-dependent and self-limiting)
Mild lipid changes (elevated LDL cholesterol and triglycerides)
Temporary glucose elevation or mildly impaired fasting glucose
Mild gastrointestinal discomfort (nausea, loose stools)
Skin changes (mild acne, slower wound healing at injection/cut sites)
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Active serious infection or immunocompromised state
Hypersensitivity to rapamycin/sirolimus or any macrolide compound
Severe hepatic impairment (rapamycin is extensively hepatically metabolized)
Planned major surgery within 2-4 weeks (impaired wound healing)
Pregnancy or breastfeeding
Concurrent use of strong CYP3A4 inhibitors without dose adjustment (ketoconazole, itraconazole, clarithromycin, grapefruit juice)
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Rapamycin Sermorelin
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest March 2023 November 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.